Campora Simona, Mohsen Reham, Passaro Daniel, Samir Howida, Ashraf Hesham, Al-Mofty Saif El-Din, Diab Ayman A, El-Sherbiny Ibrahim M, Snowden Martin J, Ghersi Giulio
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy.
Abiel s.r.l, c/o Arca Incubatore di Imprese, University of Palermo, Viale delle Scienze, Ed. 16 (Floor-2), 90128 Palermo, Italy.
Gels. 2021 Nov 8;7(4):203. doi: 10.3390/gels7040203.
Over the past several decades, the development of engineered small particles as targeted and drug delivery systems (TDDS) has received great attention thanks to the possibility to overcome the limitations of classical cancer chemotherapy, including targeting incapability, nonspecific action and, consequently, systemic toxicity. Thus, this research aims at using a novel design of Poly(-isopropylacrylamide) p(NIPAM)-based microgels to specifically target cancer cells and avoid the healthy ones, which is expected to decrease or eliminate the side effects of chemotherapeutic drugs. Smart NIPAM-based microgels were functionalized with acrylic acid and coupled to folic acid (FA), targeting the folate receptors overexpressed by cancer cells and to the chemotherapeutic drug doxorubicin (Dox). The successful conjugation of FA and Dox was demonstrated by dynamic light scattering (DLS), Fourier-transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), UV-VIS analysis, and differential scanning calorimetry (DSC). Furthermore, viability assay performed on cancer and healthy breast cells, suggested the microgels' biocompatibility and the cytotoxic effect of the conjugated drug. On the other hand, the specific tumor targeting of synthetized microgels was demonstrated by a co-cultured (healthy and cancer cells) assay monitored using confocal microscopy and flow cytometry. Results suggest successful targeting of cancer cells and drug release. These data support the use of pNIPAM-based microgels as good candidates as TDDS.
在过去几十年中,工程化小颗粒作为靶向给药系统(TDDS)的发展受到了极大关注,这是因为它有可能克服传统癌症化疗的局限性,包括靶向能力不足、非特异性作用以及由此产生的全身毒性。因此,本研究旨在利用一种基于聚(N-异丙基丙烯酰胺)(p(NIPAM))的新型微凝胶设计来特异性靶向癌细胞并避开健康细胞,有望减少或消除化疗药物的副作用。基于智能NIPAM的微凝胶用丙烯酸进行功能化,并与叶酸(FA)偶联,以靶向癌细胞过度表达的叶酸受体以及化疗药物阿霉素(Dox)。通过动态光散射(DLS)、傅里叶变换红外(FTIR)光谱、热重分析(TGA)、紫外可见(UV-VIS)分析和差示扫描量热法(DSC)证明了FA和Dox的成功偶联。此外,对癌症和健康乳腺细胞进行的活力测定表明了微凝胶的生物相容性以及偶联药物的细胞毒性作用。另一方面,通过共培养(健康细胞和癌细胞)实验,利用共聚焦显微镜和流式细胞术监测,证明了合成微凝胶对肿瘤的特异性靶向作用。结果表明成功靶向癌细胞并实现了药物释放。这些数据支持将基于pNIPAM的微凝胶作为TDDS的良好候选材料。